We report the results of a prospective, randomized phase 3 trial evaluating the use of autologous peripheral blood stem cell transplantation (ASCT) vs. intensive consolidation chemotherapy in newly diagnosed AML patients in complete remission (CR1). Patients with AML between 16-60 yrs of age in CR1 after two cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT following high-dose cyclophosphamide and busulfan. Of patients randomized (chemotherapy n=259; ASCT n=258), more than 90% received their assigned treatment arm. The two groups were comparable as regards prognostic factors. The ASCT group showed a markedly reduced relapse rate (58% vs. 70%, p=0.02) and better relapse free survival (RFS) at five years (38% vs. 29%, p= 0.065, HR 0.82 (0.66-1.1) with nonrelapse mortality of 4% vs. 1% in the chemotherapy arm (p=0.02). Overall survival (OS) was similar (44% vs. 41% at 5 years, p=0.86) due to more opportunities for salvage with second-line chemotherapy and stem cell transplantation in patients relapsing on the chemotherapy arm. This large study shows a relapse advantage for ASCT as post remission therapy but similar survival since more relapsing patients on the chemotherapy arm were salvaged with a late transplantation for relapse. This trial is registered at http://www.trialregister.nl as NTR230 and NTR291.
Introduction
Autologous bone marrow transplantation (ABMT) following marrow ablative chemotherapy or radiotherapy has originally been developed as an alternative to allogeneic stem cell transplants for patients with acute myeloid leukemia (AML) with no suitable donor. Several randomized studies in patients with AML in first complete remission (CR1) subsequently suggested reduced relapse rates following ABMT. [1] [2] [3] [4] [5] [6] For personal use only. at UNIVERSITAETSSPITAL on December 1, 2011. bloodjournal.hematologylibrary.org From However, ABMT has been associated with prolonged marrow aplasia and with an excess of non-relapse mortality. 2, 3 As a result the relapse advantage of an autologous transplant was offset by enhanced toxicity and mortality which has precluded general acceptance of ABMT as post-remission treatment in AML. [1] [2] [3] [4] [5] [6] In addition these studies with marrow auto grafts were hampered by the fact that only a minority of the allocated patients, actually underwent the transplantation. 7, 8 When hematopoietic growth factors provided the possibility to employ peripheral blood stem cells as the source of stem cells, autologous peripheral blood stem cell transplants (ASCT) offered the advantage of a markedly faster engraftment and accelerated hematological recovery as compared to marrow grafts. [9] [10] [11] The switch to ASCT was also expected to enhance compliance to protocol treatment so that a greater fraction of patients assigned to ASCT would indeed receive their intended transplantation. However, critical prospective evaluations of ASCT have remained remarkably scarce, and were performed in series with relatively small numbers of patients.
11,12
Against this background, the Dutch-Belgian HOVON and Swiss SAKK leukemia cooperative groups set out to assess the clinical benefit of ASCT following high-dose cytotoxic therapy in a multicenter study in 517 patients with AML in CR1 following intensive anthracycline and cytarabine chemotherapy. 13, 14 ASCT was prospectively compared to intensive consolidation chemotherapy with etoposide and mitoxantrone which have been reported to exert potent anti-leukemic effects.
13-15

Materials and Methods
Study Design and Chemotherapy
Previously untreated patients with a confirmed diagnosis of AML were eligible for enrollment in the HOVON/SAKK AML-29 and AML-42 trials. 13, 15 The age range for and mitoxantrone (10 mg/m 2 on days 1 through 5) in case of favorable cytogenetics and early CR after cycle I. Unfavorable risk patients were planned for an allogeneic stem cell transplantation and could be randomized in the study in case an allogeneic transplantation was not feasible. Intermediate risk patients were candidates for an HLA matched allogeneic stem cell transplantation if a donor was available and the patient fulfilled the age criteria for an allograft in their center. If allogeneic stem cell transplantation appeared no realistic option, patients could be randomized between ASCT or the third cycle of chemotherapy with etoposide and mitoxantrone.
Conditioning before ASCT consisted of high-dose chemotherapy with busulfan (4 mg/kg orally days -4 through -7 and cyclophosphamide (60 mg/kg intravenously, days -2 and -3) followed by autologous peripheral blood stem cell re-infusion (see
Supplementary Information).
This was an investigator-sponsored study with no pharma company involvement. The study was approved by ethics committees of the participating institutions and was conducted in accordance with the Declaration of Helsinki. All patients gave their written informed consent.
Prior Remission Induction Chemotherapy
For personal use only. at UNIVERSITAETSSPITAL on December 1, 2011. bloodjournal.hematologylibrary.org From Remission induction chemotherapy according the AML-29 and AML-42 protocols involved two cycles of combination chemotherapy.
13,14 Cycle 1 consisted of cytarabine (200 mg/m 2 on days 1 through 7) and idarubicin (12 mg/m 2 on days 6, 7, and 8). Cycle 2 consisted of cytarabine (1000 mg/m 2 every 12 hours on days 1 through 6) and amsacrin (120 mg/m 2 on days 4, 5, and 6). In the AML-42 protocol patients were also randomized between the aforementioned dose of cytarabine versus a more intensive cytarabine regimen (cycle 1 1000 mg/m 2 on days 1 through 5) and cycle 2 consisting of 2000 mg/m 2 twice daily on days 1, 2, 4, 6) as described. 13, 14 In the AML-29 and part of the AML-42 trial patients were randomly assigned for induction to receive granulocyte colony stimulating factor (G-CSF) or no G-CSF during cycles 1 and 2 as described.
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Criteria For Response and Endpoints
CR, relapse and overall survival (OS) were previously defined. 13, 15 Relapse-free survival (RFS) refers to the interval from randomization to the date of death, or the date of relapse. Time to hematopoietic recovery was measured from the end of chemotherapy application both for patients treated according to chemotherapy cycle III or to the transplantation group to the time when the neutrophil and the platelet counts reached values of 0.5 x 10 9 /l and 50 x 10 9 /l, respectively.
Statistical Methods
Design and Randomization
RFS was the primary endpoint. At the onset of this randomization in the AML-29 study it was clear that the number of patients randomized between third chemotherapy course and ASCT would not be sufficient to answer the question with sufficient power. Therefore the randomization was planned to be continued in the Randomized assignments to study groups were balanced with the use of a biasedcoin minimization procedure as described (see Supplementary Information),
Analysis
All analyses were performed according to the intention-to-treat principle, irrespective of patients compliance with the protocol, but 12 ineligible patients randomized between cycle III (n=5) and ASCT (n=7) were excluded: patients with acute promyelocytic leukemia (n=6); never reached CR1 (n=2); relapsed before randomization (n=2); incorrect diagnosis (n=2). Table 1 ). The recommended choice of consolidation treatment in the protocol according to the cytogenetic risk stratification (see Methods) resulted in the randomization of 34% of patients while 23% of patients went straight to consolidation chemotherapy (cycle III) and 27% were consolidated in CR1 with an allogeneic SCT depending on the availability of a HLA matched donor and clinical eligibility criteria (age, co-morbidity). Two percent of patients received an ASCT without randomization and 15% did not receive further therapy in CR1 due to early relapse or prolonged hypoplasia (Table I) . Thus, of 517 randomized patients 259 were assigned to consolidation chemotherapy cycle III and 258 patients to ASCT. Median follow-up of patients alive is 106 months (range 13-177). Nine patients in the chemotherapy group and 7 patients in the ASCT have been lost to follow-up between 1 and 12 years. The two treatment groups were matched with respect to age, cytogenetic risk, types of induction therapy (Table 2) . Ninetythree percent of the patients randomized to consolidation chemotherapy received the planned chemotherapy according protocol and 91% of the patients assigned to ASCT actually received the autologous transplant (Table 3) .
Outcome following chemotherapy or ASCT
The ASCT treatment group showed a trend towards better RFS than the chemotherapy group (38% vs. 29% at 5 years, p=0.065, HR 0.82 (0.66-1.1) ( Table 3; For personal use only. at UNIVERSITAETSSPITAL on December 1, 2011. bloodjournal.hematologylibrary.org From Figure 1 ). In the ASCT group 156 patients had recurrence of AML, while 187 patients relapsed in the chemotherapy group, corresponding with an actuarial relapse rate at 5 years of 58% and 70%, respectively (p=0.02, Table 3 ). Non-relapse mortalities (a measure of treatment-procedure related deaths) were estimated at 4% and 1% (at 5 yrs) in the ASCT and chemotherapy groups (p=0.02). OS did not differ between both treatment arms (44% vs. 41%, p=0.86). Second line anti-leukemic treatment was applied to 116 (74%) of the 156 relapsing patients in the ASCT arm which involved ASCT (n=2, 1% of recurrences), allogeneic SCT (n=27, 17%) and chemotherapy (n=87, 55%). In contrast 150 of 187 (80%) relapsing patients in the chemotherapy group were treated in second line with ASCT (n=27, 14%), allogeneic SCT (n=47, 25%) or chemotherapy (n=76, 40%). Thus a considerably greater proportion of patients following relapse in the consolidation chemotherapy group had the possibility for salvage with autologous or allogeneic stem cell transplantation (39% versus 18%). Second complete remissions were attained in 27% of the relapsed patients in the ASCT group and 47% in the chemotherapy group resulting in long term survival of 7% and 15% for patients with relapse in the ASCT group and the chemotherapy group, respectively.
Hematological Recovery And Treatment Related Toxicity
A significantly enhanced recovery of peripheral blood granulocyte count was seen following ASCT as compared to consolidation chemotherapy ( Figure 2 ). Thirty-two percent of ASCT patients reached neutrophil counts of >0.5 x 10 9 /l at day 14 and 88% on day 28 after transplant as compared to 1% and 42% respectively for patients consolidated with chemotherapy (p<.001). Platelet recovery demonstrated a biphasic pattern; in the first month after end of treatment the platelet recovery rate to >50 x 10 9 /l was slightly faster in the ASCT group (p=0.79). However, for the patients who had not recovered by that time the platelet recovery proceeded at a slower rate in the ASCT group (p<.0001, fig 2) A similar pattern was seen with respect to time to platelet transfusion independency; the median time to transfusion independency was comparable between both groups, 24 days vs. 23 days, but after that the duration was longer in the ASCT group (p=0.003). In the ASCT group the incidences of grade 3 and 4 bleedings and grade 3 and 4 infections were not different (see Supplementary Information S1). However, an increased incidence of fever of unknown origin (37% versus 21%, p<.001), gastro-intestinal (72% versus 29%, p<.001), hepatic (18% versus 6%, p<.001) and neurological (11% versus 4%, p=0.004) grade 2-4 adverse events were noted in the ASCT group. Table 4 shows the actuarial 5 year probabilities of RFS and OS and the hazard ratios in relation to clinical and hematological factors and according to treatment group.
Prognostic Factors And Subgroup Analysis
Increasing age was associated with a reduced RFS (P=0.01) and OS (P<0.001).
Presence of extra-medullary disease at diagnosis also correlated with lower RFS (P=0.016) and OS (P=0.21). Cytogenetics showed particularly strong relationships with RFS and OS. The ASCT group showed better RFS than the chemotherapy group (at 5 yrs 38% vs. 29%), but this difference was not statically significant (p=0.065). However, if the patients of the monosomal karyotype with very poor RFS in both arms were excluded, the improvement in RFS for the ASCT arm was more pronounced (p=0.014). Patients attaining late CR (i.e. after induction cycle II) had a considerably lower RFS and OS (P<.001) than those in CR already after cycle I.
In order to explore for a possible differential effect of ASCT treatment on outcome in any of the subgroups defined by the aforementioned factors, the effect of treatment was estimated separately by HR for RFS and OS with associated confidence For personal use only. at UNIVERSITAETSSPITAL on December 1, 2011. bloodjournal.hematologylibrary.org From 1 intervals combined with tests for interaction. In none of the latter analyses the test for interactions were significant (all P-values for these tests >0.10), including G-CSF priming and Ara-C dose applied.
Discussion
Randomized transplantation studies about ABMT in AML in CR1 had demonstrated reduced relapse rates in association with considerable procedural limitations including low treatment compliance, delayed hematological regeneration and increased non-relapse mortality. [1] [2] [3] [4] [5] [6] The present study demonstrates that these hurdles can largely be overcome. Autografts were successfully collected in a high number of patients and a high proportion of randomized patients did indeed receive their assigned treatment which enhanced the ability of evaluating the true value of ASCT according to intention to treat. The results show an advantage for ASCT as post-remission therapy in terms of relapse rate (57% versus 70% at 5 yrs, p=0,002) and with a higher RFS (39% versus 29% at 5 yrs, p=0,065). The OS was only slightly better after ASCT (44% vs. 41% at 5 yrs), but this difference was far from statistically significant (p=0.86). It should be noted that the similar OS value in the two groups was due to a higher proportion of successful salvage treatments, especially ASCT and allogeneic SCT, given after relapse in the chemotherapy group compared to the ASCT group.
Despite a marked accelerated granulocyte recovery in the ASCT arm more side effects were noticed likely related to more intensive chemotherapy and resulting in a treatment related mortality of 4% in the ASCT arm vs. 1% in the chemotherapy arm.
An important question is whether the choice of the remission induction therapy and the third cycle of mitoxantrone-etoposide for remission consolidation furnish a proper comparison as regards the value of ASCT. In the current study ASCT was given after Ara-C schedule made no difference. 17 In an additional study three HD-Ara-C cycles applied postremission did not yield better outcome than one cycle. 18 A large recent Japanese study has recently reinforced the notion that standard dose levels of cytarabine applied as postremission therapy are not inferior to high dose levels.
19
Our group has previously employed and applied in the standard arm of the current study an intensive treatment program involving a first induction cycle of standarddose Ara-C, a second cycle of intermediate-dose Ara-C and one third final consolidation cycle, and we have reported outcome in a range similar to that after four cycles of HD-Ara-C.
13, 15, 20
Our study does not allow a critical analysis of the value of ASCT in cytogenetically defined favorable risk and unfavorable risk subsets of AML patients because of the limited numbers of patients studied. However, the results are in line with other studies demonstrating no advantage of ASCT in patients with monosomal karyotype.
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Excluding these patients from the analysis resulted in a significant advantage in RFS for the ASCT arm (p=0.01). . [21] [22] [23] [24] One study has already demonstrated that the subset of patients with NPM1 + mutations without FLT3-internal tandem duplications (FLT3-ITD) derive no survival benefit from allogeneic SCT. 24 Direct outcome data as regards ASCT in these and other genotypes are currently not available but one might assume that the value of ASCT in these genotypic subsets will follow the cytogenetic prognostic analogies as has previously been demonstrated for allogeneic SCT.
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Allogeneic transplantation following reduced dose-intensive conditioning is nowadays quite commonly used in patients with AML because of reduced early toxicities but it involves a greater relapse rate than myelo-ablative regimens. [26] [27] [28] [29] The ability of ASCT to suppress relapse in CR1 suggests that ASCT might also have merits in AML-CR1
as a an adjunct regimen prior to allogeneic SCT. ASCT appears to minimize the leukemic burden and stabilize remissions and thus it might create better conditions and allow more time for graft versus-leukemia control. Finally, the remarkably low procedural mortality following ASCT that we report here after prolonged follow up, makes ASCT also potentially attractive for other subgroups, e.g. for favorable risk AML where it might contribute to preventing relapse.
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